A randomized controlled trial in adults with chronic migraine found that 4 weeks of noninvasive vagal nerve stimulation (nVNS) significantly reduced pain intensity, headache frequency, and migraine-related...
A recent study found that rimegepant, an orally administered calcitonin gene-related peptide receptor antagonist, is safe and well-tolerated for up to 52 weeks in individuals with migraine, with no signs of...
